Cell

Epic Bio Announces Robust Slate of Presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Poster, SAN, Cell, Abstract, Baltimore Convention Center, Gene, FSHD, Ballroom, Society, Convention, Dentistry

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Epic Bio , a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced the acceptance of six abstracts, three oral presentations, and three poster presentations at the upcoming Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Epic Bio , a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced the acceptance of six abstracts, three oral presentations, and three poster presentations at the upcoming Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland.
  • Location: Baltimore at the Baltimore Convention Center, Ballroom 1, Baltimore, Maryland
    Location: Baltimore at the Baltimore Convention Center, Ballroom III, Baltimore, Maryland
    Location: Baltimore at the Baltimore Convention Center, Ballroom III, Baltimore, Maryland
    Location: Baltimore at the Baltimore Convention Center, Exhibit Hall, Baltimore, Maryland
    Location: Baltimore at the Baltimore Convention Center, Exhibit Hall, Baltimore, Maryland

Vanqua Bio Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating VQ-101, its Small Molecule GCase Activator for GBA-Parkinson’s Disease and Related Disorders

Retrieved on: 
Tuesday, April 9, 2024
Cell, Recycling, PD, Patient, Glucocerebrosidase, Doctor of Philosophy, Alpha-synuclein, Trial of the century, Protein, Neuron, Safety, Pharmacokinetics, Lysosome

CHICAGO, April 09, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases, announced that the first patient has been dosed in a first-in-human Phase 1 clinical study evaluating VQ-101 in healthy individuals and patients with various forms of Parkinson’s disease (PD). VQ-101 is an orally administered brain-penetrant small molecule allosteric activator of the lysosomal enzyme glucocerebrosidase (GCase).

Key Points: 
  • VQ-101 is an orally administered brain-penetrant small molecule allosteric activator of the lysosomal enzyme glucocerebrosidase (GCase).
  • “VQ-101 demonstrated promising efficacy, safety, pharmacokinetics, and target engagement in preclinical studies.
  • Mutations in GBA1 are the most common genetic risk factor for PD, representing approximately 10% of patients with PD worldwide.
  • In developing VQ-101, Vanqua is adopting a precision-medicine approach that focuses initially on patients with GBA-PD, the largest genetically defined segment of PD.

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

Retrieved on: 
Tuesday, April 9, 2024
TME, Cell, Environment, Immunosuppression, IDO1, Tumor microenvironment, AACR, Neoplasm, Vaccination, Poster, Vaccine, Pharmaceutical industry

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California.

Key Points: 
  • NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California.
  • “These data build on earlier studies that demonstrated the mechanism of IO102 and IO103,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech.
  • Where high levels of IDO1 and PD-L1 expression were seen in the tumor microenvironment (TME), the IDO1 vaccine predominantly reduced myeloid-derived immune suppression, while the PD-L1 vaccine enhanced anti-tumor T-effector functions.
  • The poster can be found on the “ Posters & Publications ” page of the IO Biotech website and on the AACR website.

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Major histocompatibility complex, CPI, Cell, Entrepreneurship, Oncology, Immunotherapy, DLL4, Patient, Neoplasm, Data, Tumor microenvironment, VEGF, Checkpoint, Doctor of Philosophy, MD, Natural killer T cell, News, AACR, MHC, Research and development, Therapy, MHC-I, Antibody, Immune system, PD-L1, San Diego Convention Center, NK, PD-1, Vaccine

Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471.

Key Points: 
  • Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471.
  • The proposed mechanism for this effect suggests the involvement of NK-cells, which can generate potent cell killing independent of MHC-I.
  • Following mCTX-009 and mCTX-471 combination treatment, superior efficacy was observed in MHC Class I negative tumors.
  • A copy of the presentation materials can be accessed on the News & Events section under “ Presentations ” of the Company’s website at www.compasstherapeutics.com once the presentation has concluded.

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Euronext Growth, Gene, DNA, HSPC, Society, Therapy, Cell, Gene editing, Vaccine

Cellectis presents the development of a novel gene editing process, leveraging the TALEN® technology and non-viral DNA template delivery, enabling highly efficient gene correction and gene insertion in hematopoietic stem and progenitor cells (HSPCs).

Key Points: 
  • Cellectis presents the development of a novel gene editing process, leveraging the TALEN® technology and non-viral DNA template delivery, enabling highly efficient gene correction and gene insertion in hematopoietic stem and progenitor cells (HSPCs).
  • Gene therapy using hematopoietic and progenitor stem cells (HSPC) has the potential to provide a lifelong supply of genetically encoded therapeutics.
  • Gene editing strategies enabling supra-endogenous expression of therapeutics often rely on constitutive promoters resulting in transgene overexpression irrespective of cellular differentiation, which could be detrimental for HSPC function.
  • Full abstracts and presentations will be available on Cellectis’ website following the event:

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Retrieved on: 
Monday, April 8, 2024
TME, FAP, Cell, Immunotherapy, Colorectal cancer, Mink, Patient, Tumor microenvironment, Cancer, PST, AACR, MSS, Neoplasm, Therapy, CRC, Liver, Liver disease, Vaccine

The data presented at AACR demonstrate MiNK-215's potential to effectively combat colorectal liver metastases, offering hope for patients who have exhausted conventional treatment options,” said Dr. Jennifer Buell, President and Chief Executive Officer at MiNK.

Key Points: 
  • The data presented at AACR demonstrate MiNK-215's potential to effectively combat colorectal liver metastases, offering hope for patients who have exhausted conventional treatment options,” said Dr. Jennifer Buell, President and Chief Executive Officer at MiNK.
  • This collaboration holds promise in bolstering the anti-tumor response, particularly in the formidable realm of microsatellite stable colorectal cancer."
  • Liver mets have limited the efficacy of immunotherapy in patients with mismatch repair proficient/microsatellite-stable (pMMR/MSS) colorectal cancer (CRC).
  • MiNK's innovative iNKT cell therapy, MiNK-215, has shown the ability to remodel the immunosuppressive tumor microenvironment within the liver.

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Computational biology, Malignancy, Canadian Aviation Regulations, Gene editing, Bone disease, Cell, Hook effect, CXCR4, Enfortumab vedotin, Synthetic biology, Patient, Neoplasm, Epitope, Differentiable function, Ink, PBMC, Protein engineering, HLA, Science, Cytotoxicity, AACR, Phenotype, Therapy, IPSC, Skin, Inflammation, Prognosis, Carcinogenesis, Rejection, CD22, VHH, Poster, NK, Century, Autoimmunity, Bone marrow, Engineering, CD19, Vaccine

PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024.

Key Points: 
  • PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024.
  • This novel CAR was engineered and tested in iPSC-derived gamma-delta T cells, showing in vitro tumor cell cytotoxicity.
  • These findings support the continued examination of a CD19xCD22 bispecific CAR for off-the-shelf allogeneic cell therapy to expand patient access beyond CD19 CAR-T cell therapies.
  • In these preclinical studies, Century identified novel single-domain antibodies (VHH) that bind to multiple epitopes on the NECTIN4 extracellular domain.

Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method

Retrieved on: 
Monday, April 8, 2024
Cell, Environment, Human body, Patient, DSM-IV codes, Patent, PLUR

Pluri’s proprietary 3D cell expansion technology mimics the natural lymph node like environment that immune cells have within the human body.

Key Points: 
  • Pluri’s proprietary 3D cell expansion technology mimics the natural lymph node like environment that immune cells have within the human body.
  • The tightly controlled and fully automated bioreactor system provides cells with the conditions they need in order to expand, enabling efficient expansion of immune cells at scale and quality.
  • Pluri's patented technology marks an important milestone in the field of allogeneic cell therapy, positioning the Company at the forefront of innovation.
  • “Pluri’s patented technology represents a significant leap forward in the field of immune cell expansion, addressing the growing global demand for advanced cell-based therapies.

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 8, 2024
PRC2, Prostate cancer, Regulation, EED, Cell, Patient, CYP, SAN, Doctor of Philosophy, EZH2, AACR, TRIM37, PLK4, Optimism, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced two oral presentations on ORIC-944, a potent and selective allosteric inhibitor of PRC2, and presentation of a new discovery candidate, ORIC-613, an orally bioavailable, potent and selective PLK4 inhibitor, at the 2024 American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus competitor PRC2 inhibitors
    First data presentation on ORIC-613, a potential first- and best-in-class development candidate selectively inhibiting PLK4
    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced two oral presentations on ORIC-944, a potent and selective allosteric inhibitor of PRC2, and presentation of a new discovery candidate, ORIC-613, an orally bioavailable, potent and selective PLK4 inhibitor, at the 2024 American Association for Cancer Research (AACR) Annual Meeting.
  • “ORIC-944 in combination with AR inhibitors demonstrates anti-tumor activity in multiple AR-positive prostate cancer models, supporting the planned expansion of our ORIC-944 clinical program in combination with AR inhibitors in metastatic prostate cancer,” said Lori Friedman, PhD, chief scientific officer.
  • “These encouraging preclinical findings, coupled with potential best-in-class drug properties and deepened understanding of the mechanism driving synergy, fuel our optimism for advancing this program.
  • Additionally, the unveiling of preclinical characterization of ORIC-613, a potential first- and best-in-class selective PLK4 inhibitor, marks a significant milestone in our discovery program, with preclinical data demonstrating synthetic lethality in TRIM37-high tumors.”
    ORIC-944, a potent and selective allosteric PRC2 inhibitor with potential best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models (Presentation will be available on ORIC website on Tuesday, April 9, 2024 at 2:30 p.m. PT)
    Key findings of the presentations:
    Discovery of ORIC-944 was enabled through structure-based drug design and leveraged a cryptic pocket in an allosteric site in EED, a subunit of PRC2
    Comprehensive profiling supports ORIC-944's best-in-class properties versus competitor PRC2 inhibitors, including PF-06821497, tazemetostat, and CPI-0209:
    Clinical half-life estimated at approximately 20 hours, with no sign of CYP autoinduction that is observed with first-generation PRC2 inhibitors
    Demonstrated that EED and EZH2 inhibitors act through the same mechanism of action, making prostate cancer cells more susceptible to AR inhibition:
    Transcriptional changes induced by ORIC-944 were comparable to those of EZH2 inhibitors in prostate cancer models, indicating no mechanistic distinction between molecules targeting different core subunits of PRC2
    RNA sequencing of prostate cancer models revealed that ORIC-944 increases AR signaling and luminal cell fate, thereby rendering these cells more susceptible to AR inhibition
    ORIC-613, a potential first- and best-in-class, orally bioavailable, potent and selective PLK4 inhibitor with synthetic lethality in TRIM37 high cancer models
    Key findings of the presentation:
    ORIC-613 is an orally bioavailable, potent and exquisitely selective small molecule inhibitor of PLK4, which is synthetic lethal in tumor cells with high levels of TRIM37
    Preclinical assessment in cancer cell lines revealed synthetic lethality, with ORIC-613 inducing apoptotic tumor cell death specifically in TRIM37-high breast cancer and neuroblastoma cells versus TRIM37-wildtype cells
    These results position ORIC-613 as a potential first- and best-in-class development candidate, which has the potential to benefit patients with TRIM37-high tumors

Metagenomi to Present at Upcoming Scientific Meetings

Retrieved on: 
Monday, April 8, 2024
Congress, Patient, Gene, World Congress, World Federation of Hemophilia, MD, World government, Society, Cell, MGX, WFH, Annual general meeting, Pharmaceutical industry

EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: a late breaking oral presentation at The World Federation of Hemophilia (WFH) World Congress, taking place April 21 – 24, 2024 in Madrid, Spain and two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

Key Points: 
  • -   Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024
    -   Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8 & 9, 2024
    EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: a late breaking oral presentation at The World Federation of Hemophilia (WFH) World Congress, taking place April 21 – 24, 2024 in Madrid, Spain and two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.